Skip to Main Content

In another sign of its renewed emphasis on cancer, Sanofi (SNY) said Tuesday it will partner with the University of Texas MD Anderson Cancer Center to speed oncology research and testing of its experimental cancer drugs.

The five-year alliance, whose contractual details were not disclosed by the French pharmaceutical company or the Houston academic medical center, will bring together MD Anderson’s clinical trial system with Sanofi’s pipeline of potential cancer treatments. Sanofi signaled its intention to ramp up oncology drug development earlier this year at the American Society of Clinical Oncologists’ virtual annual meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!